Ensysce Biosciences Inc.
Ensysce Biosciences Inc. (ENSC): 3 pipeline candidates · 1 upcoming catalyst · ~1 mo cash runway · 2 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
1.0 months
D/E -8.34 · 0% dilution
Lead: Phase 3
3 candidates
1 upcoming, next in ~136d
N/A
A transparent, data-derived signal for Ensysce Biosciences Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$4.1M
Cash
$745K
Quarterly Burn
$3.5M
Runway
1.0 mo
Revenue
$961K
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (3 candidates)
| Drug | Phase |
|---|---|
| nafamostat | Phase 1 |
| pf614 | Phase 1 |
| pf614-mpar | Phase 3 |
Upcoming Catalysts (1)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
14
Total value held
$307K
| Holder | Shares | Value |
|---|---|---|
| perceptive advisors llc | 173,332 | $93K |
| adage capital partners gp, l.l.c. | 149,711 | $81K |
| geode capital management, llc | 73,880 | $40K |
| citadel advisors llc | 57,363 | $31K |
| vanguard capital management llc | 25,708 | $14K |
| xtx topco ltd | 24,363 | $13K |
| vanguard fiduciary trust co | 23,854 | $13K |
| jane street group, llc | 13,570 | $7K |
| tru independence asset management 2, llc | 13,000 | $7K |
| ubs group ag | 8,791 | $5K |
Showing top 10 of 14 institutional holders of Ensysce Biosciences Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Ensysce Biosciences Inc.'s pipeline?
Ensysce Biosciences Inc. (ENSC) has 3 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Ensysce Biosciences Inc.'s lead drug candidate?
Ensysce Biosciences Inc.'s most advanced tracked candidate is nafamostat (Phase 1) for Pharmacokinetics.
What is Ensysce Biosciences Inc.'s next catalyst?
Ensysce Biosciences Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safet" — expected November 1, 2026.
What is Ensysce Biosciences Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Ensysce Biosciences Inc. has approximately 1.0 months of cash runway.
What is Ensysce Biosciences Inc.'s market capitalization?
Ensysce Biosciences Inc.'s market capitalization is approximately $4.1M.
Get the full picture on Ensysce Biosciences Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.